Nausheen Ahmed

Assistant Professor

University of Kansas Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Nausheen Ahmed is an Assistant Professor at the University of Kansas Medical Center in the United States. Her research focuses on the clinical outcomes and efficacy of chimeric antigen receptor T cell therapies in various hematological malignancies, with particular attention to older adults and individuals with compromised health. Recent articles co-authored by Dr. Ahmed explore topics such as risk evaluation in cell therapy, real-world outcomes of novel treatments for multiple myeloma, and the effectiveness of bispecific antibodies in relapsed conditions.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (8)

James A Davis

Medical University of South Carolina

UNITED STATES

View details

Mehdi Hamadani

UNITED STATES

View details

Priyanka Pophali

Assistant Professor

University of Wisconsin-Madison

UNITED STATES

View details

Peter Riedell

University of Chicago

UNITED STATES

View details

Mazyar Shadman

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Natalie Grover

Assistant Professor

University of North Carolina at Chapel Hill School of Medicine

UNITED STATES

View details

Stephen Schuster

Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research

Hospital of the University of Pennsylvania

UNITED STATES

View details

Muhammad Umair Mushtaq

Assistant Professor of Medicine

University of Kansas Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Nausheen Ahmed

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis

From Risk to Reach: How Risk Evaluation and Mitigation Strategy Remediation Will Shape Access to Chimeric Antigen Receptor T Cell Therapy

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study

Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study

Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis

CD19-directed CART Therapy for T cell/Histiocyte Rich Large B-cell Lymphoma

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians

Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy

Dawn of Hope for Improved Access to BCMA Therapy: Chimeric Antigen Receptor T Cell and Bispecific Products

Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma

Bridging the Gap: Early Transition and Hybrid Models of Care to Improve Access to Chimeric Antigen Receptor T Cell Therapy

Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET/CT Imaging Following CAR-T Therapy

Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma

ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy

Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access

Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria

COVID-19 presenting as a viral exanthem and detected during admission prescreening in a hematopoietic cell transplant recipient

Collaborators (8)

James A Davis

Mehdi Hamadani

Priyanka Pophali

Peter Riedell

Mazyar Shadman

Natalie Grover

Stephen Schuster

Muhammad Umair Mushtaq

Make your next move.